欣普贝生应用于足月胎膜早破引产的临床分析

目的 探讨欣普贝生应用于足月胎膜早破的引产效果. 方法 选择我院70例有引产指征的足月胎膜早破孕妇,完全随机分为2组.研究组35例使用欣普贝生引产,对照组35例以缩宫素引产,比较两组的引产效果以及分娩结局. 结果 研究组12 h内促宫颈成熟有效率100%,高于对照组48.39%;研究组用药至临产时间（6.27±6.13）h,短于对照组（9.65±6.79）h,用药至分娩时间（12.15±7.51）h,也短于对照组（19.34±9.22）h;研究组剖宫产率22.86%,低于对照组45.71%（均P＜0.05）;研究组总产程（6.10±2.60）h,短于对照组（10.97±3.37）h（P＜0.05）;两组产后出血、胎儿窘迫及新生儿窒息的发生率差异均无统计学意义（P＞0.05）. 结论 欣普贝生可安全地用于足月胎膜早破的引产,效果优于缩宫素.

Clinical analysis of dinoprostone suppositories for labor induction in term premature rupture of membrane

Objective To observe the clinical effects of dinoprostone suppositories used for induction of term premature rupture of membrane(PROM). Methods Totally 70 cases of term premature rupture of membrane without any vaginal delivery tabo in The Third Affiliated Hospital were randomly divided into two group:35 cases in dinoprostone suppositories group,35 cases in oxytocin group.Induction effects and delivery outcomes were compared between two groups. Results Bishop score was increased ≥2 points in 100% cases in study group in 12 hours,whereas only 48.39% cases in control group;The time to labor starting was shortned obviously in study group(6.27 ±6.13 hours)than that in control group(9.65 ±6.79 h).The time until labor was also shortned obviously in study group(12.15 ±7.51 h)than that in control group(19.34 ±9.22 h);Cesarean section rate in study group(22.86%)was significantly lower than that of control group(45.71%);Duration of three stages was shortned obviously in study group(6.10 ± 2.60 h)than that in control group(10.97 ± 3.37 h);There was no significant difference of postpartum hemorrhage,fetal distress,neonatal asphyxia between two groups. Conclusion The use of therapy with dinoprostone suppositories in patients with PROM can be a safe method and more effective than oxytocin management.